Official Title
Role of Corticosteroid Nasal Spray in Recovery of Smell Sensation in COVID-19 Patients
Brief Summary

The aim of this study is to evaluate the role of the topical corticosteroids nasal spray (mometasone furoate nasal spray) in improving anosmia in patients recovered from COVID-19 infection.

Detailed Description

This study willbe submitted on patients who recently recovered from proven COVID-19 infection
and complaining of anosmia or hyposmia.The proven COVID-19 infection will be relied on a
positive real-time reverse transcription polymerase chain reaction (rRT-PCR) with samples
obtained by a nasopharyngeal swab. The recovery is defined as 2 consecutives negative
(rRT-PCR) samples.

Complete medical history will be taken, and essential clinical assessment with appropriate
protective measures will be performed in all patients.The patients in the study will be
randomly divided into two groups: - Group I: -who will receive topical corticosteroid nasal
spray (mometasone furoate nasal spray) beside olfactory training Group II: -who will not
receive topical corticosteroid nasal spray but only olfactory training.

As regards the assessment of smell,the patient will assess his smell sensation using familiar
substances with distinctive odor. A jar of coffee, a branch of mint and garlic are some used
substances. The patient will report the degree of anosmia subjectively with score on a scale
from 0 to 10.The assessment of smell will be done initially after recovery/discharge, after 1
week, 2 weeks and after 3 weeks for all patients. The duration of smell loss will be recorded
from the onset of anosmia till full recovery of the sensation.

Completed
COVID19
Anosmia

Drug: mometasone furoate nasal spray

dose of 2 puff in each nostril (100 µg once daily each nostril).
Other Name: steroid nasal spray

Eligibility Criteria

Inclusion Criteria:

- adults 18 yrs or older patients

- confirmed case (+ve PCR),

- recovered/discharged (2 -ve PCR),

- suffered from sudden recent anosmia or hyposmia

Exclusion Criteria:

- patients already on nasal steroid

- with previous chronic rhinological pathologies,

- patients on systemic steroid for previous systemic disease,

- anosmia improved before COVID19 recovery,

- pregnancy

- patients who will not complete the follow up period.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Egypt
Locations

Benha University Hospital, Faculty of Medicine
Banhā, Qalubia, Egypt

Benha University
NCT Number
Keywords
COVID19
anosmia
mometasone nasal spray
MeSH Terms
COVID-19
Anosmia
Mometasone Furoate